Mediar Therapeutics
Mediar Therapeutics is a clinical stage company advancing first-in-class therapies to halt fibrosis progression.
55 employees · est. 2019 · Boston, United States
RADBIO
Developing a therapeutic platform targeting TGF-beta, the "master regulator of fibrosis"
7 employees · est. 2018 · San Carlos, United States
RADBIO is the older company (2019 vs 2018); Mediar Therapeutics is the larger of the two.
Side-by-Side Comparison
| Metric | Mediar Therapeutics | RADBIO |
|---|---|---|
| Founded | ||
| Founded | 2019 | 2018 older |
| Headquarters | ||
| Headquarters | Boston, United States | San Carlos, United States |
| Employees | ||
| Employees | 55 larger | 7 |
| Industry | ||
| Industry | Biotechnology, Health Care, Health and Wellness | Biopharma, Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Series A | Not tracked yet |
| Total Funding | ||
| Total Funding | $85.00M | Not tracked yet |
| Funding Rounds | ||
| Funding Rounds | 3 | Not tracked yet |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Biotech Company, Fibrosis Treatment, Preclinical Stage, Novel Targets, Blood Biomarkers, Disease Progression, Clinical Development | Therapeutic Platform, TGF-beta, Fibrosis Treatment, Genetic Engineering, Drug Development, Biomolecule Therapy, Research And Development, Biomarkers, Biopharmaceutical, Diagnosis, Solid Tumors, Neutralizing Biomolecule, Delivery Strategies |
| Website | ||
| Website | mediartx.com | radbiopharm.com |
About Mediar Therapeutics
Mediar Therapeutics is a preclinical stage biotech company with a mission to develop innovative treatments to halt or even reverse fibrosis. The company takes a pioneering approach by targeting the fibrotic mediators driving disease progression. Founded in 2019, Mediar is deeply rooted in its unders...
About RADBIO
RADBIO is a biopharmaceutical startup focusing on developing a therapeutic platform targeting TGF-beta, known as the "master regulator of fibrosis." Fibrosis, a significant factor in the cause of death for many diseases, lacks effective treatments to halt or reverse its progression, despite existing...
We will tell you when either one moves
BounceWatch watches Mediar Therapeutics and RADBIO for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Mediar Therapeutics and RADBIO — by email.
Frequently Asked Questions
Compare Mediar Therapeutics with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Mediar Therapeutics on 9 Jun 2026, and RADBIO on 27 Oct 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.